A technical information page focused on composition, practical use, rationale and selected scientific literature concerning ingredients and bioactive compounds relevant to the product. The purpose is educational, not promotional, and the content is intended to support a medical-scientific discussion [1][2][3][4][5].
According to the ISF technical sheet, Gastronyx Plus is a food supplement based on Aloysia triphylla and an Ajuga reptans cell-culture extract, both used for digestive function, with Althaea officinalis supporting a soothing and emollient effect on the digestive tract [1].
It may be considered as an adjunct nutritional option, within an appropriate diet and after clinical assessment, in subjects with:
This page does not present Gastronyx Plus as a pharmacological alternative to PPIs or other treatments. The product is not positioned as an antacid and is not intended to diagnose, treat or cure disease. Use should always be framed within professional clinical judgement [1][6].
1 tablet daily, swallowed or dissolved in the mouth. Preferably in the morning on waking or in the evening before bedtime; avoid food or drink for about 15 minutes after intake. It can be taken either with or without food [1].
| Ingredient | Amount / 1 tablet | Standardisation | Functional note |
|---|---|---|---|
| Aloysia triphylla dry extract | 76 mg | Acteosides 19 mg | Digestive function [1][2] |
| Althaea officinalis root extract | 60 mg | Mucilage 12 mg | Soothing and emollient effect on the digestive system [1] |
| Ajuga reptans / Teupol 10P | 30 mg | Teupolioside 3 mg | Preclinical interest in intestinal inflammatory pathways [1] |
| Pharmaceutical form | 30 orodispersible tablets, 500 mg each [1] | ||
The product rationale rests on three complementary pillars:
In practical terms, this medical page frames the product as nutritional support focused on mucosa, digestive function and a phytonutritional rationale, rather than as a simple acid-neutralising approach.
The evidence summarised below includes preclinical studies and technical/regulatory documents on individual compounds or extracts relevant to the product profile. References are reported transparently and should not be read as definitive clinical proof for the finished product [1][2][3][4][5].
The review by Alipieva et al. describes verbascoside as a phenylethanoid glycoside with antioxidant and anti-inflammatory activities. More recent literature, also reflected in the ISF technical sheet, discusses interactions with NF-κB, TNF-α, IL-1β, COX-2, iNOS and pathways such as MAPK and PI3K/AKT [1][3].
The EMA assessment report on Aloysia citrodora describes a history of traditional use in the digestive area, including dyspepsia, gastrointestinal complaints, stomach ache and indigestion. This supports the traditional-use context; it is not direct clinical evidence in GERD [2].
In an animal model of 5-FU-induced mucositis, verbascoside attenuated increases in inflammatory and tissue-damage biomarkers, alongside histological improvement across the gastrointestinal tract, from the oesophagus to the colon [5].
López-Rodríguez et al. evaluated fractions and isolated compounds from Castilleja tenuiflora in an experimental stress-induced gastric lesion model. In that setting, verbascoside markedly reduced ulcerated area, with inhibition close to 99.8% compared with the vehicle group [4].
In the 2025 Medical Oncology study, 5-fluorouracil induced widespread biochemical and histological alterations in the gastrointestinal tract. Verbascoside attenuated these changes, with a trend towards better outcomes at the higher dose [5].
| Parameter | Effect of 5-FU | Reported effect of verbascoside |
|---|---|---|
| TNF-α, IL-1β | Increase | Attenuation of the increase [5] |
| MMP-1, MMP-2, MMP-8 | Increase | Reduction / attenuation [5] |
| TIMP-1 | Decrease | Trend towards recovery [5] |
| ALP, AST, LDH | Increase | Attenuation [5] |
| Oesophagus-to-colon histology | Degeneration and desquamation | Improved organisation / re-epithelialisation [5] |
The EMA/HMPC report on Aloysia citrodora provides regulatory and historical context for interpreting the formulation. The document refers to traditional uses associated with:
Value of the data: it supports the digestive-use coherence of Aloysia within the formula, while remaining distinct from specific clinical proof in reflux disease.
The internal technical sheet suggests the product as an adjunct in gastric reflux symptoms, heartburn, gastritis, slow digestion and difficult digestion [1]. In this conservative medical page, it is positioned mainly as nutritional support for digestive and gastro-oesophageal discomfort.
Food supplements should not be used as a substitute for a varied, balanced diet and a healthy lifestyle. Keep out of reach of children under 3 years of age. Excessive consumption may have laxative effects. Store in a cool, dry place [1].
Gastronyx Plus is available through pharmacies and directly at the company’s operational premises in Trento: Via Alla Veduta 84, 38121 Trento, Italy. Local availability and access can be checked through the company.
